[{"id":"083ff2b4-1c8e-4316-85e8-ab1466391065","acronym":"","url":"https://clinicaltrials.gov/study/NCT03301168","created_at":"2021-01-18T16:18:29.964Z","updated_at":"2024-07-02T16:36:07.482Z","phase":"Phase 1/2","brief_title":"Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant","source_id_and_acronym":"NCT03301168","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 05/11/2021","primary_completion_date":" 05/11/2021","study_txt":" Completion: 05/01/2034","study_completion_date":" 05/01/2034","last_update_posted":"2022-07-12"},{"id":"773a0191-6552-426c-b8bb-0477e9718c29","acronym":"","url":"https://clinicaltrials.gov/study/NCT02477878","created_at":"2021-01-18T11:55:57.064Z","updated_at":"2024-07-02T16:36:07.467Z","phase":"Phase 1","brief_title":"Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant","source_id_and_acronym":"NCT02477878","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 01/14/2020","primary_completion_date":" 01/14/2020","study_txt":" Completion: 01/01/2033","study_completion_date":" 01/01/2033","last_update_posted":"2022-07-12"},{"id":"8f85763f-e649-4c88-96b6-c0ae0f05eac2","acronym":"","url":"https://clinicaltrials.gov/study/NCT01744223","created_at":"2021-01-18T07:37:40.124Z","updated_at":"2024-07-02T16:36:07.432Z","phase":"Phase 1/2","brief_title":"Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant","source_id_and_acronym":"NCT01744223","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" FLT3 • KMT2A • HLA-DRB1 • HLA-B","pipe":" | ","alterations":" MLL rearrangement • MLL rearrangement • Chr t(9;11)","tags":["FLT3 • KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement • MLL rearrangement • Chr t(9;11)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 10/09/2019","primary_completion_date":" 10/09/2019","study_txt":" Completion: 10/01/2032","study_completion_date":" 10/01/2032","last_update_posted":"2022-07-12"},{"id":"b105d23b-a787-4c0a-81db-551a2e374a07","acronym":"","url":"https://clinicaltrials.gov/study/NCT03459170","created_at":"2021-01-18T17:03:10.004Z","updated_at":"2024-07-02T16:36:07.436Z","phase":"Phase 1","brief_title":"Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant","source_id_and_acronym":"NCT03459170","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/01/2018","start_date":" 02/01/2018","primary_txt":" Primary completion: 09/01/2022","primary_completion_date":" 09/01/2022","study_txt":" Completion: 09/01/2035","study_completion_date":" 09/01/2035","last_update_posted":"2022-07-12"},{"id":"4553806e-e0c4-4db4-ab84-19a652b71c6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02786485","created_at":"2021-01-18T13:40:12.832Z","updated_at":"2024-07-02T16:36:40.372Z","phase":"Phase 1","brief_title":"Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT","source_id_and_acronym":"NCT02786485","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2020-10-05"},{"id":"837927b2-eb6b-4652-92eb-3c2283ccc219","acronym":"","url":"https://clinicaltrials.gov/study/NCT02487459","created_at":"2021-01-18T11:58:41.219Z","updated_at":"2024-07-02T16:36:40.421Z","phase":"Phase 1/2","brief_title":"Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies","source_id_and_acronym":"NCT02487459","lead_sponsor":"Bellicum Pharmaceuticals","biomarkers":" FLT3 • KMT2A • HLA-DRB1 • HLA-B","pipe":" | ","alterations":" FLT3 mutation • MLL rearrangement • Chr del(5q) • Chr del(7q)","tags":["FLT3 • KMT2A • HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation • MLL rearrangement • Chr del(5q) • Chr del(7q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 06/01/2017","primary_completion_date":" 06/01/2017","study_txt":" Completion: 06/01/2017","study_completion_date":" 06/01/2017","last_update_posted":"2020-10-05"},{"id":"510d6f44-a072-43a1-b8bd-ade22d9eb8d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03807063","created_at":"2021-01-18T18:48:54.843Z","updated_at":"2024-07-02T16:36:41.993Z","phase":"Phase 1","brief_title":"Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant","source_id_and_acronym":"NCT03807063","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" MLL rearrangement","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CaspaCIDe DLI (rimiducid activated rivogenlecleucel) • rimiducid (AP1903)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/02/2020","start_date":" 01/02/2020","primary_txt":" Primary completion: 12/31/2020","primary_completion_date":" 12/31/2020","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2020-08-14"}]